Aadi Bioscience, Inc. is a commercial-stage biopharmaceutical company. Co. is focused on developing and commercializing precision therapies for cancers with alterations in the mammalian target of rapamycin (mTOR) pathway, a regulator of cell growth and cancer progression. Its lead drug product, FYARRO, is an mTOR inhibitor indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO is a form of sirolimus bound to albumin. Sirolimus is a potent inhibitor of the mTOR biological pathway and inhibits downstream signaling from mTOR, which can promote tumor growth. We show 13 historical shares outstanding datapoints in our AADI shares outstanding history coverage, used to compute AADI market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AADI market cap history over the course of time is important for investors
interested in comparing AADI's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AADI versus a peer is one thing; comparing
AADI market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AADI can fluctuate over the course of history.
With this page we aim to empower investors researching AADI by allowing them to research the AADI market cap history. |
Free AADI Email Alerts:
Video: The Importance of Market Cap
